GlassScriptPhysician profile
Andrew F Vasconcellos
NPI 1649518317
$1,578.90
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,443 · 2023: $80.26 · 2024: $55.59.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $135.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $459.67 | 2019-2024 | Enbrel, Krystexxa, Prolia |
| Abbvie INC. | $218.95 | 2019-2023 | Rinvoq |
| Ucb, INC. | $189.73 | 2019-2024 | Bimzelx |
| Janssen Biotech, INC. | $185.43 | 2019 | |
| Lilly USA, LLC | $129.30 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $98.53 | 2019 | |
| Radius Health, INC. | $74.93 | 2019 | |
| Glaxosmithkline, LLC. | $56.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.79 | 2019-2023 | |
| Genentech USA, INC. | $38.09 | 2019 | |
| Horizon Therapeutics Plc | $25.11 | 2023 | Krystexxa |
| Sobi, INC | $20.37 | 2019 | |
| Celgene Corporation | $19.64 | 2019 | |
| Pfizer INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Vasconcellos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.